Low threshold T-type calcium channels as targets for novel epilepsy treatments

British Journal of Clinical Pharmacology

Volumn 77, Issue 5, 2014, Pages 729-739

  Powell, Kim L ^a   Cain, Stuart M ^b   Snutch, Terrance P ^b   O'Brien, Terence J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

anti epileptic drugs; epilepsy; T type calcium channels

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; ETHOSUXIMIDE; MESUXIMIDE; MIBEFRADIL; PHENYTOIN; SUCCINIMIDE; SUCCINIMIDE DERIVATIVE; VALPROATE SEMISODIUM; VALPROIC ACID; VOLTAGE GATED CALCIUM CHANNEL; ZONISAMIDE;

BIOPHYSICS; DISEASE CLASSIFICATION; DRUG TARGETING; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; GENERALIZED EPILEPSY; HUMAN; INSOMNIA; MOLECULAR BIOLOGY; NOMENCLATURE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEIZURE; TEMPORAL LOBE EPILEPSY; ANIMAL; CLASSIFICATION; DISEASE MODEL; SLEEP;

ANIMALS; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS; SLEEP;

EID: 84899121774     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12205     Document Type: Review

References (102)

1. Alexander SP, Mathie A, Peters JA,. Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 2011; 164 (Suppl. 1): S1-324.
2. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J,. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005; 57: 411-425.
3. Perez-Reyes E,. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003; 83: 117-161.
4. Kozlov AS, McKenna F, Lee JH, Cribbs LL, Perez-Reyes E, Feltz A, Lambert RC,. Distinct kinetics of cloned T-type Ca2 + channels lead to differential Ca2 + entry and frequency-dependence during mock action potentials. Eur J Neurosci 1999; 11: 4149-4158.
5. Chemin J, Monteil A, Perez-Reyes E, Bourinet E, Nargeot J, Lory P,. Specific contribution of human T-type calcium channel isotypes (alpha(1G), alpha(1H) and alpha(1I)) to neuronal excitability. J Physiol 2002; 540: 3-14.
6. Cain SM, Snutch TP,. Contributions of T-type calcium channel isoforms to neuronal firing. Channels (Austin) 2010; 4: 475-482.
7. Williams SR, Toth TI, Turner JP, Hughes SW, Crunelli V,. The 'window' component of the low threshold Ca2+ current produces input signal amplification and bistability in cat and rat thalamocortical neurones. J Physiol 1997; 505 (Pt 3): 689-705.
8. Dreyfus FM, Tscherter A, Errington AC, Renger JJ, Shin HS, Uebele VN, Crunelli V, Lambert RC, Leresche N,. Selective T-type calcium channel block in thalamic neurons reveals channel redundancy and physiological impact of I(T)window. J Neurosci 2010; 30: 99-109.
9. Talley EM, Cribbs LL, Lee JH, Daud A, Perez-Reyes E, Bayliss DA,. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci 1999; 19: 1895-1911.
10. McKay BE, McRory JE, Molineux ML, Hamid J, Snutch TP, Zamponi GW, Turner RW,. Ca (V)3 T-type calcium channel isoforms differentially distribute to somatic and dendritic compartments in rat central neurons. Eur J Neurosci 2006; 24: 2581-2594.
11. McRory JE, Santi CM, Hamming KS, Mezeyova J, Sutton KG, Baillie DL, Stea A, Snutch TP,. Molecular and functional characterization of a family of rat brain T-type calcium channels. J Biol Chem 2001; 276: 3999-4011.
12. Murbartian J, Arias JM, Lee JH, Gomora JC, Perez-Reyes E,. Alternative splicing of the rat Ca(v)3.3 T-type calcium channel gene produces variants with distinct functional properties(1). FEBS Lett 2002; 528: 272-278.
13. Emerick MC, Stein R, Kunze R, McNulty MM, Regan MR, Hanck DA, Agnew WS,. Profiling the array of Ca(v)3.1 variants from the human T-type calcium channel gene CACNA1G: alternative structures, developmental expression, and biophysical variations. Proteins 2006; 64: 320-342.
14. Zhong X, Liu JR, Kyle JW, Hanck DA, Agnew WS,. A profile of alternative RNA splicing and transcript variation of CACNA1H, a human T-channel gene candidate for idiopathic generalized epilepsies. Hum Mol Genet 2006; 15: 1497-1512.
15. Broicher T, Kanyshkova T, Landgraf P, Rankovic V, Meuth P, Meuth SG, Pape HC, Budde T,. Specific expression of low-voltage-activated calcium channel isoforms and splice variants in thalamic local circuit interneurons. Mol Cell Neurosci 2007; 36: 132-145.
16. Powell KL, Kyi M, Reid CA, Paradiso L, D'Abaco GM, Kaye AH, Foote SJ, O'Brien TJ,. Genetic absence epilepsy rats from Strasbourg have increased corticothalamic expression of stargazin. Neurobiol Dis 2008; 31: 261-265.
17. David LS, Garcia E, Cain SM, Thau E, Tyson JR, Snutch TP,. Splice-variant changes of the Ca(V)3.2 T-type calcium channel mediate voltage-dependent facilitation and associate with cardiac hypertrophy and development. Channels (Austin) 2010; 4: 375-389.
18. Molineux ML, McRory JE, McKay BE, Hamid J, Mehaffey WH, Rehak R, Snutch TP, Zamponi GW, Turner RW,. Specific T-type calcium channel isoforms are associated with distinct burst phenotypes in deep cerebellar nuclear neurons. Proc Natl Acad Sci USA 2006; 103: 5555-5560.
19. Hildebrand ME, Isope P, Miyazaki T, Nakaya T, Garcia E, Feltz A, Schneider T, Hescheler J, Kano M, Sakimura K, Watanabe M, Dieudonne S, Snutch TP,. Functional coupling between mGluR1 and Cav3.1 T-type calcium channels contributes to parallel fiber-induced fast calcium signaling within Purkinje cell dendritic spines. J Neurosci 2009; 29: 9668-9682.
20. Isope P, Hildebrand ME, Snutch TP,. Contributions of T-type voltage-gated calcium channels to postsynaptic calcium signaling within Purkinje neurons. Cerebellum 2012; 11: 651-665.
21. Contreras D,. The role of T-channels in the generation of thalamocortical rhythms. CNS Neurol Disord Drug Targets 2006; 5: 571-585.
22. Crunelli V, Cope DW, Hughes SW,. Thalamic T-type Ca2+ channels and NREM sleep. Cell Calcium 2006; 40: 175-190.
23. Manni R, Terzaghi M,. Comorbidity between epilepsy and sleep disorders. Epilepsy Res 2010; 90: 171-177.
24. Parrino L, Halasz P, Tassinari CA, Terzano MG,. CAP, epilepsy and motor events during sleep: the unifying role of arousal. Sleep Med Rev 2006; 10: 267-285.
25. Parrino L, Smerieri A, Spaggiari MC, Terzano MG,. Cyclic alternating pattern (CAP) and epilepsy during sleep: how a physiological rhythm modulates a pathological event. Clin Neurophysiol 2000; 111 (Suppl. 2): S39-46.
26. Ferrillo F, Beelke M, Nobili L,. Sleep EEG synchronization mechanisms and activation of interictal epileptic spikes. Clin Neurophysiol 2000; 111 (Suppl. 2): S65-73.
27. Phillips MC, Costello CA, White EJ, Smit M, Carino J, Strawhorn A, Jackson B, Kwan P, French CR, Yerra SR, Tan KM, O'Brien TJ, Goldin J,. Routine polysomnography in an epilepsy monitoring unit. Epilepsy Res 2013; 105: 401-404.
28. Manni R, Terzaghi M, Arbasino C, Sartori I, Galimberti CA, Tartara A,. Obstructive sleep apnea in a clinical series of adult epilepsy patients: frequency and features of the comorbidity. Epilepsia 2003; 44: 836-840.
29. Hughes SW, Cope DW, Toth TI, Williams SR, Crunelli V,. All thalamocortical neurones possess a T-type Ca2+ 'window' current that enables the expression of bistability-mediated activities. J Physiol 1999; 517 (Pt 3): 805-815.
30. 2+ channel plays a crucial role in stabilizing sleep. Proc Natl Acad Sci U S A 2005; 102: 1743-1748.
31. Kraus RL, Li Y, Gregan Y, Gotter AL, Uebele VN, Fox SV, Doran SM, Barrow JC, Yang ZQ, Reger TS, Koblan KS, Renger JJ,. In vitro characterization of T-type calcium channel antagonist TTA-A2 and in vivo effects on arousal in mice. J Pharmacol Exp Ther 2010; 335: 409-417.
32. Uebele VN, Gotter AL, Nuss CE, Kraus RL, Doran SM, Garson SL, Reiss DR, Li Y, Barrow JC, Reger TS, Yang ZQ, Ballard JE, Tang C, Metzger JM, Wang SP, Koblan KS, Renger JJ,. Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. J Clin Invest 2009; 119: 1659-1667.
33. Tringham E, Powell KL, Cain SM, Kuplast K, Mezeyova J, Weerapura M, Eduljee C, Jiang X, Smith P, Morrison JL, Jones NC, Braine E, Rind G, Fee-Maki M, Parker D, Pajouhesh H, Parmar M, O'Brien TJ, Snutch TP,. T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. Sci Transl Med 2012; 4: 121ra19.
34. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE,. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51: 676-685.
35. World Health Organization. Epilepsy. 2012. Fact Sheet No 999. Available at http://www.who.int/mediacentre/factsheets/fs999/en/ (last accessed 29 July 2013).
36. Kwan P, Brodie MJ,. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
37. Tsakiridou E, Bertollini L, de Curtis M, Avanzini G, Pape HC,. Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy. J Neurosci 1995; 15: 3110-3117.
38. Ernst WL, Zhang Y, Yoo JW, Ernst SJ, Noebels JL,. Genetic enhancement of thalamocortical network activity by elevating alpha 1g-mediated low-voltage-activated calcium current induces pure absence epilepsy. J Neurosci 2009; 29: 1615-1625.
39. Kim D, Song I, Keum S, Lee T, Jeong MJ, Kim SS, McEnery MW, Shin HS,. Lack of the burst firing of thalamocortical relay neurons and resistance to absence seizures in mice lacking alpha(1G) T-type Ca(2+) channels. Neuron 2001; 31: 35-45.
40. 2+ channel causes a long-lasting modification of neuronal firing mode after status epilepticus. J Neurosci 2002; 22: 3645-3655.
41. Becker AJ, Pitsch J, Sochivko D, Opitz T, Staniek M, Chen CC, Campbell KP, Schoch S, Yaari Y, Beck H,. Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. J Neurosci 2008; 28: 13341-13353.
42. Sanabria ER, Su H, Yaari Y,. Initiation of network bursts by Ca2+-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy. J Physiol 2001; 532: 205-216.
43. Faas GC, Vreugdenhil M, Wadman WJ,. Calcium currents in pyramidal CA1 neurons in vitro after kindling epileptogenesis in the hippocampus of the rat. Neuroscience 1996; 75: 57-67.
44. Morimoto K, Fahnestock M, Racine RJ,. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004; 73: 1-60.
45. Graef JD, Nordskog BK, Wiggins WF, Godwin DW,. An acquired channelopathy involving thalamic T-type Ca2+ channels after status epilepticus. J Neurosci 2009; 29: 4430-4441.
46. Yaari Y, Yue C, Su H,. Recruitment of apical dendritic T-type Ca2+ channels by backpropagating spikes underlies de novo intrinsic bursting in hippocampal epileptogenesis. J Physiol 2007; 580: 435-450.
47. Chen Y, Lu J, Pan H, Zhang Y, Wu H, Xu K, Liu X, Jiang Y, Bao X, Yao Z, Ding K, Lo WH, Qiang B, Chan P, Shen Y, Wu X,. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 2003; 54: 239-243.
48. Heron SE, Khosravani H, Varela D, Bladen C, Williams TC, Newman MR, Scheffer IE, Berkovic SF, Mulley JC, Zamponi GW,. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. Ann Neurol 2007; 62: 560-568.
49. Vitko I, Chen Y, Arias JM, Shen Y, Wu XR, Perez-Reyes E,. Functional characterization and neuronal modeling of the effects of childhood absence epilepsy variants of CACNA1H, a T-type calcium channel. J Neurosci 2005; 25: 4844-4855.
50. 2+ channels: a paradigm for childhood absence epilepsy mutations. J Neurosci 2007; 27: 322-330.
51. Powell KL, Cain SM, Ng C, Sirdesai S, David LS, Kyi M, Garcia E, Tyson JR, Reid CA, Bahlo M, Foote SJ, Snutch TP, O'Brien TJ,. A Cav3.2 T-type calcium channel point mutation has splice-variant-specific effects on function and segregates with seizure expression in a polygenic rat model of absence epilepsy. J Neurosci 2009; 29: 371-380.
52. Wang J, Zhang Y, Liang J, Pan H, Wu H, Xu K, Liu X, Jiang Y, Shen Y, Wu X,. CACNA1I is not associated with childhood absence epilepsy in the Chinese Han population. Pediatr Neurol 2006; 35: 187-190.
53. Chen Y, Lu J, Zhang Y, Pan H, Wu H, Xu K, Liu X, Jiang Y, Bao X, Zhou J, Liu W, Shi G, Shen Y, Wu X,. T-type calcium channel gene alpha (1G) is not associated with childhood absence epilepsy in the Chinese Han population. Neurosci Lett 2003; 341: 29-32.
54. Singh B, Monteil A, Bidaud I, Sugimoto Y, Suzuki T, Hamano S, Oguni H, Osawa M, Alonso ME, Delgado-Escueta AV, Inoue Y, Yasui-Furukori N, Kaneko S, Lory P, Yamakawa K,. Mutational analysis of CACNA1G in idiopathic generalized epilepsy. Mutation in brief #962. Online. Hum Mutat 2007; 28: 524-525.
55. Song I, Kim D, Choi S, Sun M, Kim Y, Shin HS,. Role of the alpha1G T-type calcium channel in spontaneous absence seizures in mutant mice. J Neurosci 2004; 24: 5249-5257.
56. Broicher T, Kanyshkova T, Meuth P, Pape HC, Budde T,. Correlation of T-channel coding gene expression, IT, and the low threshold Ca2+ spike in the thalamus of a rat model of absence epilepsy. Mol Cell Neurosci 2008; 39: 384-399.
57. Talley EM, Solorzano G, Depaulis A, Perez-Reyes E, Bayliss DA,. Low-voltage-activated calcium channel subunit expression in a genetic model of absence epilepsy in the rat. Brain Res Mol Brain Res 2000; 75: 159-165.
58. Galanopoulou AS, Buckmaster PS, Staley KJ, Moshe SL, Perucca E, Engel J Jr, Loscher W, Noebels JL, Pitkanen A, Stables J, White HS, O'Brien TJ, Simonato M,. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012; 53: 571-582.
59. Blumenfeld H, Klein JP, Schridde U, Vestal M, Rice T, Khera DS, Bashyal C, Giblin K, Paul-Laughinghouse C, Wang F, Phadke A, Mission J, Agarwal RK, Englot DJ, Motelow J, Nersesyan H, Waxman SG, Levin AR,. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 2008; 49: 400-409.
60. Dezsi G, Ozturk E, Stanic D, Powell KL, Blumenfeld H, O'Brien TJ, Jones NC,. Ethosuximide reduces epileptogenesis and behavioural comorbidity in the GAERS model of genetic generalised epilepsy. Epilepsia 2013; 54: 635-643.
61. Russo E, Citraro R, Scicchitano F, De Fazio S, Di Paola ED, Constanti A, De Sarro G,. Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. Epilepsia 2010; 51: 1560-1569.
62. Russo E, Citraro R, Scicchitano F, De Fazio S, Perrotta I, Di Paola ED, Constanti A, De Sarro G,. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia 2011; 52: 1341-1350.
63. Bialer M,. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012; 64: 887-895.
64. McGivern JG,. Pharmacology and drug discovery for T-type calcium channels. CNS Neurol Disord Drug Targets 2006; 5: 587-603.
65. Goren MZ, Onat F,. Ethosuximide: from bench to bedside. CNS Drug Rev 2007; 13: 224-239.
66. Coulter DA, Huguenard JR, Prince DA,. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989; 25: 582-593.
67. Coulter DA, Huguenard JR, Prince DA,. Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol 1990; 100: 800-806.
68. Crunelli V, Leresche N,. Block of thalamic T-type Ca(2+) channels by ethosuximide is not the whole story. Epilepsy Curr 2002; 2: 53-56.
69. Leresche N, Parri HR, Erdemli G, Guyon A, Turner JP, Williams SR, Asprodini E, Crunelli V,. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J Neurosci 1998; 18: 4842-4853.
70. 2+ channel antagonist on thalamic relay and local circuit interneurons in a rat model of absence epilepsy. Neuropharmacology 2007; 53: 431-446.
71. Leppik IE, Willmore LJ, Homan RW, Fromm G, Oommen KJ, Penry JK, Sackellares JC, Smith DB, Lesser RP, Wallace JD,. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993; 14: 165-173.
72. Biton V,. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007; 30: 230-240.
73. Czapinski P, Blaszczyk B, Czuczwar SJ,. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5: 3-14.
74. Rock DM, Macdonald RL, Taylor CP,. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989; 3: 138-143.
75. Kito M, Maehara M, Watanabe K,. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996; 5: 115-119.
76. Kaneko S, Okada M, Hirano T, Kondo T, Otani K, Fukushima Y,. Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread. Jpn J Psychiatry Neurol 1993; 47: 371-373.
77. 2+ channel on acetylcholine release in rat frontal cortex. Epilepsy Res 2002; 49: 49-60.
78. +, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124: 1277-1285.
79. Ueda Y, Doi T, Tokumaru J, Willmore LJ,. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003; 116: 1-6.
80. Takahashi Y, Hashimoto K, Tsuji S,. Successful use of zonisamide for central poststroke pain. J Pain 2004; 5: 192-194.
81. Murata M,. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 2004; 10: 687-693.
82. Murata M, Horiuchi E, Kanazawa I,. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 2001; 41: 397-399.
83. Loscher W,. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669-694.
84. Jeavons PM, Clark JE,. Sodium valproate in treatment of epilepsy. Br Med J 1974; 15: 584-586.
85. Loscher W, Schmidt D,. Increase of human plasma GABA by sodium valproate. Epilepsia 1980; 21: 611-615.
86. Loscher W, Siemes H,. Valproic acid increases gamma-aminobutyric acid in CSF of epileptic children. Lancet 1984; 2: 225.
87. Patsalos PN,. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 2005; 46 (Suppl. 9): 140-148.
88. VanDongen AM, VanErp MG, Voskuyl RA,. Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia 1986; 27: 177-182.
89. Zeise ML, Kasparow S, Zieglgansberger W,. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991; 544: 345-348.
90. Gean PW, Huang CC, Hung CR, Tsai JJ,. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices. Brain Res Bull 1994; 33: 333-336.
91. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS,. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
92. MacDonald JL, Roskams AJ,. Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation. Prog Neurobiol 2009; 88: 170-183.
93. Todorovic SM, Perez-Reyes E, Lingle CJ,. Anticonvulsants but not general anesthetics have differential blocking effects on different T-type current variants. Mol Pharmacol 2000; 58: 98-108.
94. Twombly DA, Yoshii M, Narahashi T,. Mechanisms of calcium channel block by phenytoin. J Pharmacol Exp Ther 1988; 246: 189-195.
95. Kobrinsky EM, Pearson HA, Dolphin AC,. Low- and high-voltage-activated calcium channel currents and their modulation in the dorsal root ganglion cell line ND7-23. Neuroscience 1994; 58: 539-552.
96. Lory P, Chemin J,. Towards the discovery of novel T-type calcium channel blockers. Expert Opin Ther Targets 2007; 11: 717-722.
97. Barton ME, Eberle EL, Shannon HE,. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione and mibefradil. Eur J Pharmacol 2005; 521: 79-85.
98. Moosmang S, Haider N, Bruderl B, Welling A, Hofmann F,. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2. Circ Res 2006; 98: 105-110.
99. Gackiere F, Bidaux G, Lory P, Prevarskaya N, Mariot P,. A role for voltage gated T-type calcium channels in mediating 'capacitative' calcium entry? Cell Calcium 2006; 39: 357-366.
100. Yang ZQ, Barrow JC, Shipe WD, Schlegel KA, Shu Y, Yang FV, Lindsley CW, Rittle KE, Bock MG, Hartman GD, Uebele VN, Nuss CE, Fox SV, Kraus RL, Doran SM, Connolly TM, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Marino MJ, Graufelds VK, DiLella AG, Reynolds IJ, Vargas HM, Bunting PB, Woltmann RF, Magee MM, Koblan KS, Renger JJ,. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem 2008; 51: 6471-6477.
101. Shipe WD, Barrow JC, Yang ZQ, Lindsley CW, Yang FV, Schlegel KA, Shu Y, Rittle KE, Bock MG, Hartman GD, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Uebele VN, Nuss CE, Connolly TM, Doran SM, Fox SV, Kraus RL, Marino MJ, Graufelds VK, Vargas HM, Bunting PB, Hasbun-Manning M, Evans RM, Koblan KS, Renger JJ,. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist. J Med Chem 2008; 51: 3692-3695.
102. Uebele VN, Nuss CE, Fox SV, Garson SL, Cristescu R, Doran SM, Kraus RL, Santarelli VP, Li Y, Barrow JC, Yang ZQ, Schlegel KA, Rittle KE, Reger TS, Bednar RA, Lemaire W, Mullen FA, Ballard JE, Tang C, Dai G, McManus OB, Koblan KS, Renger JJ,. Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys 2009; 55: 81-93.